With reference to its letter No. JPL/CS/1899/2023 dated 7th February, 2023, Jenburkt Pharmaceuticals has informed that it enclosed, clippings of two Newspapers, The Free Press Journal, Mumbai (English) and Navshakti, Mumbai (Marathi) dated 8th February, 2023 containing the standalone Unaudited Financial Results of the Company for the quarter and nine months ended on 31st December, 2022.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1669.30 |
| Dr. Reddys Lab | 1234.00 |
| Cipla | 1231.50 |
| Zydus Lifesciences | 937.50 |
| Lupin | 2329.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: